Program
zodasiran
Also written as “ARO-ANG3”, “Zodasiran” and “zodasiran Injection”.
Its studies are mostly in Homozygous Familial Hypercholesterolemia · Dyslipidemias, led by Arrowhead Pharmaceuticals.
Furthest: phase 3, since Jun 17, 20254 company-led studies, 2 open or runningNext primary completion: Aug 20, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 42 open or running | phase 3since Jun 17, 2025 | Nov 16, 2018 | Aug 20, 2027phase 3 · NCT07037771 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2018First study: phase 1 study in DyslipidemiasFirst studyNCT03747224 · 93 enrolled · Australia, New Zealand
- Apr 2, 2021Phase 2 study in Mixed DyslipidemiaNCT04832971 · 204 enrolled · United States, Australia, Canada and more
- Jun 17, 2025Phase 3 study in Homozygous Familial HypercholesterolemiaNCT07037771 · 70 enrolled · United States, Australia, Austria and more
- Mar 11, 2026Phase 3 study in Homozygous Familial HypercholesterolemiaNCT07473843 · 10 planned · United States, Denmark, Poland
Ahead
- Aug 20, 2027Primary completion: phase 3 study in Homozygous Familial HypercholesterolemiaNCT07037771
- Jul 2028Primary completion: phase 3 study in Homozygous Familial HypercholesterolemiaNCT07473843
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07473843Homozygous Familial Hypercholesterolemia · United States, Denmark, Poland | 3 | Recruiting | Jul 2028 | 10 |
| NCT07037771Homozygous Familial Hypercholesterolemia · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 20, 2027 | 70 |
| NCT04832971Mixed Dyslipidemia · United States, Australia, Canada and more | 2 | Completed | Aug 30, 2022 | 204 |
| NCT03747224Dyslipidemias · Australia, New Zealand | 1 | Completed | May 17, 2021 | 93 |
How it is read
Names in the registry
- “ARO-ANG3”, 2 entries
- “Zodasiran”, 1 entry
- “zodasiran Injection”, 1 entry
Conditions, from the studies’ own filings
- Homozygous Familial Hypercholesterolemia, 2 studies
- Dyslipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.